CD33 and renal cell adenocarcinoma: On the other hand, human M-MDSCs have been described as CD14+HLA-DR−(CD33+Lin−) in hepatocellular carcinoma, metastatic prostate cancer, renal cell cancer, and malignant melanoma [28–31].